Dose-schedule studies with hydroxyurea (NSC-32065) in malignant melanoma.
D000284:Administration, Oral; D000328:Adult; D000577:Amides / Q000494:pharmacology; D005260:Female; D006801:Humans; D006918:Hydroxyurea / Q000008:administration & dosage* / Q000009:adverse effects / Q000494:pharmacology; D007093:Imidazoles / Q000494:pharmacology; D007275:Injections, Intravenous; D007970:Leukopenia / Q000139:chemically induced; D008113:Liver Neoplasms / Q000188:drug therapy; D008175:Lung Neoplasms / Q000188:drug therapy; D008297:Male; D008545:Melanoma / Q000188:drug therapy*; D008875:Middle Aged; D009362:Neoplasm Metastasis; D009588:Nitrogen Mustard Compounds / Q000494:pharmacology; D009607:Nitrosourea Compounds / Q000494:pharmacology; D012075:Remission, Spontaneous; D012878:Skin Neoplasms / Q000188:drug therapy; D013921:Thrombocytopenia / Q000139:chemically induced; D013997:Time Factors; D014750:Vincristine / Q000494:pharmacology; D014839:Vomiting / Q000139:chemically induced
D000577:Amides; D007093:Imidazoles; D009588:Nitrogen Mustard Compounds; D009607:Nitrosourea Compounds; D014750:Vincristine; D006918:Hydroxyurea